Itrack Global Data Registry To Support The Role Of Canaloplasty For Treatment Of Glaucoma

The iTrack^TM Global Data Registry (iTGDR) is a prospective, multicenter, real-world study of patients with primary and secondary open angle glaucoma undergoing canaloplasty using the iTrack^TM or iTrack^TM Advance devices (Nova Eye Inc., Fremont, USA). Canaloplasty lowers intraocular pressure by targeting the three main sites of outflow resistance: the trabecular meshwork, Schlemm’s canal and the distal collector channels. During the surgical procedure, a flexible microcatheter is advanced 360-degrees around Schlemm’s canal. As the microcatheter is withdrawn, viscoelastic fluid is injected to dilate Schlemm’s canal, collector channel ostia and the distal outflow system. 

Multicenter global cloud-based database

The iTGDR is a surgeon-led initiative conducted in collaboration with the International Glaucoma Surgery Registry (IGSR). The IGSR is an independent cloud-based platform that collates high quality longitudinal data on the outcomes of glaucoma surgery and has been recognised by the European Glaucoma Society and the Australian New Zealand Glaucoma Society. The iTGDR will collate efficacy, safety and canaloplasty specific treatment parameters such as intraocular pressure (IOP), number of glaucoma medications, pachymetry values, adverse events and complications.

The iTGDR commenced in January 2022 with approximately 20 sites in the USA, Canada, Europe, Asia and Australia. Canaloplasty outcomes will be followed for a minimum of 12-months and up to 24 to 60 months. A minimum of 300 patients will be enrolled. It will generate analytics and reports of outcomes for each participating site as well as the entire iTGDR. 

The iTGDR will make a major contribution to understanding the clinical effectiveness of canaloplasty to guide evidence-based decision making for surgeons to achieve improved outcomes in the treatment of their glaucoma patients.